Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Co-Occurring EGFR L858R Mutation and HER2 Amplification in NSCLC Identified by Stepwise Molecular Profiling.

The American journal of case reports - 2 Sept 2026

Kadyrbayeva Rabiga, Kaidarova Dilyara, Moldasheva Aisha, Smagulova Kaldygul Kabakovna, Turkpenova Innara, Orazgalieva Madina, Ossikbayeva Saniya Omirkhanovna, Satbayeva Elvira, Makarov Valeriy

Abstract excerpt

BACKGROUND The coexistence of multiple oncogenic drivers in non-small cell lung cancer (NSCLC) is a rare and diagnostically challenging molecular configuration. Conventional polymerase chain reaction (PCR)-based testing may fail to detect co-occurring genomic alterations, potentially limiting therapeutic options, particularly in resource-constrained settings. CASE REPORT We describe the case of a 54-year-old...

Read the complete abstract on PubMed

Topics

Humans
Female
Lung Neoplasms
Middle Aged
ErbB Receptors
Erb-b2 Receptor Tyrosine Kinases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Mutation

Carcinoma, Non-Small-Cell Lung

Gene Amplification

In Situ Hybridization, Fluorescence

Source

Open in PubMed Open full text

Identifiers

PMID: 42681853
DOI: 10.12659/AJCR.953829
PMCID: PMC13548814

Genes

EGFR
ERBB2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 26 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Co-Occurring EGFR L858R Mutation and HER2 Amplification in NSCLC Identified by Stepwise Molecular Profiling.PMID 42681853Read ↗

A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.Semantic proximity Read ↗

Implementation of Real-World Diagnostic Strategies in Taiwan for the Identification of Targetable Oncogenic Driver Alterations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.Semantic proximity Read ↗

EGFR-mutant NSCLC: monitoring the molecular evolution of tumors in 2022.Semantic proximity Read ↗

Actionable Gene Alterations in Resected Non-Small Cell Lung Cancer: Primary Results From the AGA-R Study.Semantic proximity Read ↗

A Retrospective, Multicenter Analysis Within the National Network Genomic Medicine Lung Cancer in Germany to Detect RET Fusions as a Possible Mechanism of Resistance in Patients With EGFR Mutations.Semantic proximity Read ↗

De Novo EGFR -ALK and EGFR -ROS1 Co-Mutations in NSCLC: Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis.Semantic proximity Read ↗

Co-Occurring Driver Genomic Alterations in Advanced Non-Small-Cell Lung Cancer (NSCLC): A Retrospective AnalysisSemantic proximity Read ↗

Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.Semantic proximity Read ↗

[Clinicopathological, molecular characteristics and prognostic analysis of non-small cell lung cancer with HER-2 genetic variations].Semantic proximity Read ↗

A radio-genomics biomarker for precision epidermal growth factor receptor mutation targeting therapy in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.